

ONE HUNDRED THIRTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

July 29, 2014

Dr. Jay P. Siegel
Chief Biotechnology Officer and
Head of Global Regulatory Affairs
Janssen Pharmaceutical Companies of
Johnson & Johnson
1125 Trenton-Harbourton Road
Titusville, NJ 08560

Dear Dr. Siegel:


Thank you for appearing before the Subcommittee on Health on Wednesday, July 9, 2014, to testify at the hearing entitled "21st Century Cures: Modernizing Clinical Trials."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Tuesday, August 12, 2014. Your responses should be mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to Sydne.Harwick@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,


Joseph R. Pitts
Chairman
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

Attachment—Additional Questions for the Record

The Honorable John Shimkus

1. You state in your testimony that “advances in next generation sequencing, imaging and molecular diagnostics (e.g. proteomics) are contributing to our understanding of how and why drugs may have different effects in different individuals with the same diagnosis.” In what ways can such genomic sequencing and molecular diagnostics help support subpopulation drug and device development?

2. What types of barriers do you believe Congress needs to address to ensure that the potential of precision medicine can be realized by both developers and clinicians?